Novo-Catalent deal could hurt smaller drugmakers who lack strong access to contract manufacturing, Roche CEO says
MLex Summary: Blockbuster obesity drug manufacturer Novo Holding's proposed acquisition of Catalent — a medical contract development and manufacturing organization, or CDMO, — "doesn't make sense" from a competition standpoint and...To view the full article, register now.
Already a subscriber? Click here to view full article